Q32 Bio Sells Lead Product Candidate to Akebia Therapeutics

Dow Jones

Dec 01

By Connor Hart

Q32 Bio said it sold the lead product candidate from its tissue-targeted complement inhibitor platform to Akebia Therapeutics.

The Waltham, Mass., biotech company said Monday it will receive $12 million in upfront payments and a near-term milestone. Q32 Bio said it will be eligible to receive a total of up to $592 million, pending the achievement of certain development, regulatory and commercial milestones, in addition to tiered royalties of up to a mid-teen percent of annual net sales.

The transaction will strengthen the company's cash position, extending its runway into the second half of 2027, while also enabling it to focus on the advancement of bempikibart, its treatment for autoimmune and inflammatory diseases, Q32 Bio said.

Shares of Q32 jumped 78% in premarket trading, to $3.90, while Akebia's stock was roughly flat.

Akebia said the product candidate, AKB-097, is believed to have applicability across a wide range of complement-mediated rare kidney diseases.

"While our commercial and medical teams continue to build on the momentum of our Vafseo launch, we are excited to take an important step forward as a company with the establishment of our rare kidney disease development pipeline," Akebia Chief Executive John Butler said.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

December 01, 2025 07:46 ET (12:46 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2588727118"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588727118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588727118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588727118","market":"fut","top_or_hot":-1,"title":"Q32 Bio Sells Lead Product Candidate to Akebia Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/QTTB\">Q32 Bio</a> said it sold the lead product candidate from its tissue-targeted complement inhibitor platform to Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  The Waltham, Mass., biotech company said Monday it will receive $12 million in upfront payments and a near-term milestone. Q32 Bio said it will be eligible to receive a total of up to $592 million, pending the achievement of certain development, regulatory and commercial milestones, in addition to tiered royalties of up to a mid-teen percent of annual net sales. \n</p>\n<p>\n  The transaction will strengthen the company's cash position, extending its runway into the second half of 2027, while also enabling it to focus on the advancement of bempikibart, its treatment for autoimmune and inflammatory diseases, Q32 Bio said. \n</p>\n<p>\n  Shares of Q32 jumped 78% in premarket trading, to $3.90, while Akebia's stock was roughly flat. \n</p>\n<p>\n  Akebia said the product candidate, AKB-097, is believed to have applicability across a wide range of complement-mediated rare kidney diseases. \n</p>\n<p>\n  \"While our commercial and medical teams continue to build on the momentum of our Vafseo launch, we are excited to take an important step forward as a company with the establishment of our rare kidney disease development pipeline,\" Akebia Chief Executive John Butler said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 01, 2025 07:46 ET (12:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Q32 Bio Sells Lead Product Candidate to Akebia Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQ32 Bio Sells Lead Product Candidate to Akebia Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-01 20:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/QTTB\">Q32 Bio</a> said it sold the lead product candidate from its tissue-targeted complement inhibitor platform to Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  The Waltham, Mass., biotech company said Monday it will receive $12 million in upfront payments and a near-term milestone. Q32 Bio said it will be eligible to receive a total of up to $592 million, pending the achievement of certain development, regulatory and commercial milestones, in addition to tiered royalties of up to a mid-teen percent of annual net sales. \n</p>\n<p>\n  The transaction will strengthen the company's cash position, extending its runway into the second half of 2027, while also enabling it to focus on the advancement of bempikibart, its treatment for autoimmune and inflammatory diseases, Q32 Bio said. \n</p>\n<p>\n  Shares of Q32 jumped 78% in premarket trading, to $3.90, while Akebia's stock was roughly flat. \n</p>\n<p>\n  Akebia said the product candidate, AKB-097, is believed to have applicability across a wide range of complement-mediated rare kidney diseases. \n</p>\n<p>\n  \"While our commercial and medical teams continue to build on the momentum of our Vafseo launch, we are excited to take an important step forward as a company with the establishment of our rare kidney disease development pipeline,\" Akebia Chief Executive John Butler said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 01, 2025 07:46 ET (12:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKBA","symbol_name":"Akebia Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2588727118","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588727118","pubTimestamp":1764593160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Q32 Bio said it sold the lead product candidate from its tissue-targeted complement inhibitor platform to Akebia Therapeutics.The Waltham, Mass., biotech company said Monday it will receive $12 million in upfront payments and a near-term milestone. Q32 Bio said it will be eligible to receive a total of up to $592 million, pending the achievement of certain development, regulatory and commercial milestones, in addition to tiered royalties of up to a mid-teen percent of annual net sales.The transaction will strengthen the company's cash position, extending its runway into the second half of 2027, while also enabling it to focus on the advancement of bempikibart, its treatment for autoimmune and inflammatory diseases, Q32 Bio said.Shares of Q32 jumped 78% in premarket trading, to $3.90, while Akebia's stock was roughly flat.Akebia said the product candidate, AKB-097, is believed to have applicability across a wide range of complement-mediated rare kidney diseases.\"While our commercial and","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKBA":"Akebia Therapeutics, Inc.","BK4139":"生物科技","QTTB":"Q32 Bio Inc."},"translate_title":"Q32 Bio向Akebia Therapeutics出售主要候选产品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QTTB":0.9,"AKBA":1.5},"content_text":"By Connor Hart \n\n\n \n\n\nQ32 Bio said it sold the lead product candidate from its tissue-targeted complement inhibitor platform to Akebia Therapeutics. \n\n\n  The Waltham, Mass., biotech company said Monday it will receive $12 million in upfront payments and a near-term milestone. Q32 Bio said it will be eligible to receive a total of up to $592 million, pending the achievement of certain development, regulatory and commercial milestones, in addition to tiered royalties of up to a mid-teen percent of annual net sales. \n\n\n  The transaction will strengthen the company's cash position, extending its runway into the second half of 2027, while also enabling it to focus on the advancement of bempikibart, its treatment for autoimmune and inflammatory diseases, Q32 Bio said. \n\n\n  Shares of Q32 jumped 78% in premarket trading, to $3.90, while Akebia's stock was roughly flat. \n\n\n  Akebia said the product candidate, AKB-097, is believed to have applicability across a wide range of complement-mediated rare kidney diseases. \n\n\n  \"While our commercial and medical teams continue to build on the momentum of our Vafseo launch, we are excited to take an important step forward as a company with the establishment of our rare kidney disease development pipeline,\" Akebia Chief Executive John Butler said. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 07:46 ET (12:46 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}